Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
patience will get you .005 here.
just a matter of time now.
Cant buy that one. Hope you make a profit there and recoup.
Too much selling here. I’m out. DPUI Has a tiny float. Filing out. Looks ready to break out. Jus sayin
What else is cooking in OTC land? You from Canada right? I think RSPI is setting up.
I miss it .0025 bottom and try chase .0029 after 12 mil ask break ...no luck. I stop chase....it will go back down coming day gtvh
Buy GTVH looks good, can’t buy it because I’m located in Europe. Fussssbal.
Biochem....dilutor around level 2 here ...u can only make money here flip it! Good luck
I tried selling today but was not quick enough.
Investors are starting to realize there might be more here than they thought
Yes the bids are good sized at times, and the chart is shaping up. That’s what’s keeping me ‘patient’ for the moment
You could also wander who is buying shares??? Everyone knows there is a lot of cd tho the volume keeps pouring.
Multi Day Runner... dont think will pull back this time!! Lets see.... Fingers X'd (and eyes)
Struc
How many effing notes are there geez
It will move down so the noteholders can exit with the fluff PR. Nothing will happen until a supposed partnership or Phase 1B trials start.
There's been a lot going on there might be a bigger PR or filings coming once the flippers get out we might see a nice move north
Lol. But still won’t move. Unreal
Nice news..flying out of the gate...
PR released today, although nothing spectacular on the horizon.
Currently, the Company’s intellectual property portfolio consists of 93 patents filed in major global jurisdictions relating to the use of PRP against solid tumors.
We look forward to executing our plans to advance PRP into a Phase 1b clinical study in advanced cancer patients, as a novel therapy for the treatment and prevention of metastatic cancer from solid tumors by targeting and eradicating CSCs, but without the side effects normally associated with standard treatment approaches.”
Good question . Need some answers here . My response was very generic.
Wonder what the ss is now..last update on the 9th.
Gonna be ugly but they all got a run in em
we expect an update on the 8k put out today ? Need a PR stating direction and what is in the pipe line . Dilution at these levels killing PPS . Thank you
Dear Thomas,
Thank you for your feedback.
As a pre-revenue development stage company, we have raised small amounts of debt to service our operating capital needs.
Rest assured, we have a direction and plans for financing, which will enable us to advance our lead asset, PRP, into the clinic.
Those plans will be revealed in due course, so please continue to refer to the company’s website and future press releases.
We appreciate your support.
Kind Regards,
Propanc IR Team
I recieved my email from the 8k day and nothing out of the ordinary. I will copy and paste today sometime .
So I wonder where the bottom is here? Or…is there even a bottom
Looks like it slowed down today let's see some filings and have a good week
Yeah, hope the bleeding stops at some point. Looks like it stopped running for now.
It’s been a long time since I’ve been in such a pos non stop diluter. Wow
Too many fucking clowns trying to flip this for beer.
Some updates about the human trials.
Go. Ppcb. Herc. What news are you expecting?
I agree this could be a really good week
Looks to me like dilution is winding down.
If they're done selling this could really take off there's a lot of potential here
This is well over .002 once we get the news.
I am hanging on to my shares.
I really thought this one would have amounted to more than it has. Oh well. It’s the otc
BBAR MM on my level 2. First time I've seen this MM.
Very helpful. Thanks.
Hahahaha. Follow the rhetoric of the bashtards!!!! This means we heading to a spike in the PPS !! Allele Capital will see to this. Too funny these basher morons.
Time will tell. But if the dilution doesn’t finally stop, there’s no way in hell this will see the .003’s again
THE CLOWN DANCE CAME TO AN END FAST...THE CIRCUS PULLED OUT OF TOWN QUICK..LMAO
Trips? Likely but not a given. I think the company will keep us up-to-date, they need exposure and consistent volume to keep up with dilution.
At some point in time we should see the Reg-A financing take place to get us to clinical trials. The compassionate use study is why this has spiked to $0.0037 to begin with. For the meantime, we are oscillating.
The accumulation line continuously nose dives. If the relentless selling doesn’t end, this will be in the trips soon
Another $100K circulated in PPCB on a Friday. Follow the money.
Followers
|
425
|
Posters
|
|
Posts (Today)
|
1
|
Posts (Total)
|
49024
|
Created
|
05/18/14
|
Type
|
Free
|
Moderators |
This section maintained by INV4
Offering New Hope to Cancer Patients and Their Caregivers
About Propanc Biopharma, Inc. The Company’s novel proenzyme therapy is based on the science that enzymes stimulate biological reactions in the body, especially enzymes secreted by the pancreas. These pancreatic enzymes could represent the body’s primary defense against cancer. A Long-Term Therapy Based on a Pancreatic Proenzyme Formulation Developing Long-Term Therapy for the Treatment of Solid Tumors Technology Based on Pancreatic Proenzyme Therapy Treatments that Inhibit Tumor Growth and Metastasis Our Lead Product: PRP Technology Based on Pancreatic Enzyme Therapy More than one hundred years ago, Professor John Beard first proposed that the pancreatic enzymes represent the body’s primary defense against cancer and would be useful as a cancer treatment. Since then, several scientists have endorsed Beard´s hypothesis with encouraging data from patient treatment. |
Click here for the video (with sound)
====================== PPCB SECURITY DETAILS ======================
Share Structure
Market Cap | 1,652,679 | 02/27/2023
Authorized Shares | 10,000,000,000 | 02/13/2023
Outstanding Shares | 1,836,310,391 | 02/13/2023
Restricted | 194,354,827 | 02/13/2023
Unrestricted | 1,641,955,564 | 02/13/2023
Held at DTC | 1,641,916,456 | 02/13/2023
Board of Directors James Nathanielsz has served as a director and Chief Executive Officer of our company since October 2007. From July 2006 until October 2007, Mr. Nathanielsz served as the New Products Manager of Biota Holdings Limited, an anti-infective drug development company in Australia. Mr. Nathanielsz was selected as a director because he is the Co-Founder of Propanc and for his experience in R&D and manufacturing and distribution. Mr. Nathanielsz holds a B.App.Sci in Biochemistry/Applied Chemistry and an M.E.I. from Swinburne University of Technology in Melbourne, Australia. ============== Dr. Julian Kenyon founded our company and was appointed as a director on February 12, 2008. Since 2000, Dr. Kenyon has served as an integrated medical physician and Medical Director of the Dove Clinic for Integrated Medicine in Winchester and London. He was the Founder-Chairman of the British Medical Acupuncture Society in 1980 and Co-Founder of the Centre for the Study of Complementary Medicine in Southampton and London. Dr. Kenyon was selected as a director because he is the Co-Founder of the Australian subsidiary and the business is based on his initial work at the Dove Clinic. Dr. Kenyon holds an M.B.Ch.B. and M.D. from the University of Liverpool Since 1972, he was appointed a Primary Fellow of the Royal College of Surgeons, Edinburgh. ============== Mr Zelinger is a Certified Practicing Accountant with 45 years of experience in tax, auditing, finance, investment and management consulting. Mr Zelinger also has significant expertise in property management and import/export businesses. Mr Zelinger commenced his career as an accountant at L.M. Stanton & Partners - Chartered Accountants, subsequently joining Caston Pty Ltd in 1980, a steel manufacturer as Chief Financial Officer, and Company Director, until 1983. Since the mid-1980’s until current date, Mr Zelinger serves as Director in several private investment companies in a range of businesses including property portfolio manager of commercial real estate, import/export businesses and a range of commercial and financial investment companies. Since 1980, Mr Zelinger also operates as a sole practitioner in accountancy and tax consulting. In 1973, Mr Zelinger graduated in Accounting and admitted as a Fellow of RMIT University in Business. He has been a Certified Practicing Accountant since 1984. Mr. Zelinger is a shareholder of Propanc Biopharma Inc. since 2010. ======================================================================== Company Info Industry Classifications |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |